Lumason (sulfur hexafluoride) Disease Interactions
There is 1 disease interaction with Lumason (sulfur hexafluoride):
Contrast Agents (Includes Lumason) ↔ Cardiopulmonary Reactions
Severe Potential Hazard, High plausibility
Applies to: Heart Disease
Serious, potentially fatal cardiopulmonary reactions have infrequently occurred during or following the injection of ultrasound contrast agents including sulfur hexafluoride and perfluten. Most serious reactions have been observed within 30 minutes of administration. Patients with unstable cardiopulmonary conditions such as acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias may be at increased risk for developing these reactions. Patients receiving these agents should be monitored for acute reactions including cardiac or respiratory arrest, shock, syncope, symptomatic arrhythmias (e.g., atrial fibrillation, tachycardia, bradycardia, supraventricular tachycardia, ventricular fibrillation, ventricular tachycardia), hypertension, hypotension, dyspnea, hypoxia, chest pain, respiratory distress, stridor, wheezing, loss of consciousness, and convulsions. Cardiopulmonary resuscitation personnel and equipment should be readily available at all times.
These agents should be used with caution in patients with known or suspected right-to-left, bidirectional, or transient right-to-left cardiac shunts. In such patients, concerns exist that some of the intravenously injected lipid- containing microspheres may bypass filtering by the lung and directly enter the arterial circulation. Occlusion of the microcirculation by these microspheres may result in tissue ischemia. Patients should be closely monitored after administration and assessed for any embolism phenomena.
Lumason (sulfur hexafluoride) drug Interactions
There is 1 drug interaction with Lumason (sulfur hexafluoride)
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.